PMCB 株価分析 — PHARMACYTE BIOTECH INC (Healthcare >> Biotechnology)
PMCB に関するよくある質問
PMCBのPER(株価収益率)は?
PHARMACYTE BIOTECH INC(PMCB)は現在PER 119.93倍で取引されています。
PMCBのROE(自己資本利益率)は?
PHARMACYTE BIOTECH INCのROEは-1,376.50%です。
PMCBの配当利回りは?
PHARMACYTE BIOTECH INCの配当利回りは0.00%です。
PMCBの品質スコア(Quality Score)は?
当社のAIはPMCBの総合財務品質を100点中46点と評価しています。収益性・成長性・負債・利益の安定性に基づく評価です。
PMCBは今が買い時ですか?
当社AIのタイミングスコアは100点中0点で、テクニカル指標とモメンタムから見た現在価格の相対的な魅力度を示します。
PMCBはどのセクターに属しますか?
PHARMACYTE BIOTECH INCはHealthcare >> Biotechnologyセクターに分類されます(NASDAQ市場)
PMCB AI Analysis Summary
Our AI summary for PMCB: PHARMACYTE BIOTECH INC (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 119.93, ROE of -1,376.50%, a dividend yield of 0.00%. Its financial Quality Score stands at 46/100 — fundamentals below the market average. The AI Timing Score is 0/100 — most technical signals do not support an entry at this point. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 0.58
Price
-0.02
(-4.00%)
Day Change
|
|
|---|
PMCB, ファンダメンタルスコアはnot good ( ファンダメンタル = 46) そして テクニカルスコアは ...(Sign In to See)...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
P/Eが高い。割高銘柄。
ROEが低い
ROAが低い
平均ROEが低い
ROEが昨年度比で低い
昨年度のROAが一昨年比で低い
NPMが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not quite good , financial health is not good , and ability to make profit is not good , ...
| Deepscope 分析 |
|
52% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 89 |
| Magic Formula Rank by ROA |
1494
|
| Magic Formula Rank by ROE |
1494
|
| Magic Formula Rank by ROIC |
1632
|
| Price | 0.58 |
| PBV / Sector |
N/A / 5.20
|
| Earning Per Share | -1,000,000.00 |
| PE / Sector |
119.93 / 19.97
|
| PEG or PE/Growth / Sector |
0.02 / 1.22
GREAT
|
| Average 1M Daily Value |
0.08 M
GREAT
|
| Average 1W Daily Value |
0.13 M
GREAT
|
| Timing Factors |
|
57% |
| Financial Health |
|
41% |
| ポイントになる統計 |
|
37% |
| 配当 |
|
4% |
| 登録情報 |
| Analyze Date | 2026-08-01 08:00:20 |
| Symbol | PMCB |
| Name | PHARMACYTE BIOTECH INC |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 10.74 M |
| Par Value | N/A |
| Calculated From | YearEnd |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 1,498.75 / 9,903.94 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 3960 Howard Hughes Parkway, Las Vegas, NV, United States, 89169
Phone: 917 595 2850
Website: https://pharmacyte.com
Sector: Healthcare >> Biotechnology
Description: PharmaCyte Biotech, Inc., a biotechnology company, focused on developing and preparing to commercialize cellular therapies for cancer using live cell encapsulation technology in the United States. The company's cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer. It also develops CypCaps for pancreatic cancer and other solid cancerous tumors. It has a cooperation agreement with Iroquois Master Fund Ltd.; license agreements with SG Austria Pte. Ltd.; and Austrianova Singapore Pte. Ltd. to use the Cell-in-the-Box technology for cancer treatment. The company was formerly known as Nuvilex, Inc. and changed its name to PharmaCyte Biotech, Inc. in January 2015. PharmaCyte Biotech, Inc. was incorporated in 1996 and is headquartered in Las Vegas, Nevada.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
Google